Loading…

Hydrogen gas with extracorporeal cardiopulmonary resuscitation improves survival after prolonged cardiac arrest in rats

Despite the benefits of extracorporeal cardiopulmonary resuscitation (ECPR) in cohorts of selected patients with cardiac arrest (CA), extracorporeal membrane oxygenation (ECMO) includes an artificial oxygenation membrane and circuits that contact the circulating blood and induce excessive oxidative...

Full description

Saved in:
Bibliographic Details
Published in:Journal of translational medicine 2021-11, Vol.19 (1), p.462-462, Article 462
Main Authors: Yin, Tai, Becker, Lance B, Choudhary, Rishabh C, Takegawa, Ryosuke, Shoaib, Muhammad, Shinozaki, Koichiro, Endo, Yusuke, Homma, Koichiro, Rolston, Daniel M, Eguchi, Shuhei, Ariyoshi, Tadashi, Matsumoto, Asami, Oka, Kentaro, Takahashi, Motomichi, Aoki, Tomoaki, Miyara, Santiago J, Nishikimi, Mitsuaki, Sasaki, Junichi, Kim, Junhwan, Molmenti, Ernesto P, Hayashida, Kei
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the benefits of extracorporeal cardiopulmonary resuscitation (ECPR) in cohorts of selected patients with cardiac arrest (CA), extracorporeal membrane oxygenation (ECMO) includes an artificial oxygenation membrane and circuits that contact the circulating blood and induce excessive oxidative stress and inflammatory responses, resulting in coagulopathy and endothelial cell damage. There is currently no pharmacological treatment that has been proven to improve outcomes after CA/ECPR. We aimed to test the hypothesis that administration of hydrogen gas (H ) combined with ECPR could improve outcomes after CA/ECPR in rats. Rats were subjected to 20 min of asphyxial CA and were resuscitated by ECPR. Mechanical ventilation (MV) was initiated at the beginning of ECPR. Animals were randomly assigned to the placebo or H gas treatment groups. The supplement gas was administered with O through the ECMO membrane and MV. Survival time, electroencephalography (EEG), brain functional status, and brain tissue oxygenation were measured. Changes in the plasma levels of syndecan-1 (a marker of endothelial damage), multiple cytokines, chemokines, and metabolites were also evaluated. The survival rate at 4 h was 77.8% (7 out of 9) in the H group and 22.2% (2 out of 9) in the placebo group. The Kaplan-Meier analysis showed that H significantly improved the 4 h-survival endpoint (log-rank P = 0.025 vs. placebo). All animals treated with H regained EEG activity, whereas no recovery was observed in animals treated with placebo. H therapy markedly improved intra-resuscitation brain tissue oxygenation and prevented an increase in central venous pressure after ECPR. H attenuated an increase in syndecan-1 levels and enhanced an increase in interleukin-10, vascular endothelial growth factor, and leptin levels after ECPR. Metabolomics analysis identified significant changes at 2 h after CA/ECPR between the two groups, particularly in D-glutamine and D-glutamate metabolism. H therapy improved mortality in highly lethal CA rats rescued by ECPR and helped recover brain electrical activity. The underlying mechanism might be linked to protective effects against endothelial damage. Further studies are warranted to elucidate the mechanisms responsible for the beneficial effects of H on ischemia-reperfusion injury in critically ill patients who require ECMO support.
ISSN:1479-5876
1479-5876
DOI:10.1186/s12967-021-03129-1